HYDRASHIFT
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
About HYDRASHIFT
Therapeutic monoclonal antibody (mAb) inclusion in Multiple Myeloma treatment regimens offer patients significant improvements in clinical outcomes. daratumumab and isatuximab are human mAb targeting CD38 used in Multiple Myeloma treatment regimens.
HYDRASHIFT avoids therapeutic mAb interference on Immunofixation interpretation assays.
Key benefits
Unique shift technology
HYDRASHIFT daratumumab and HYDRASHIFT isatuximab avoid daratumumab or isatuximab interference on HYDRAGEL IF tests.
Trust in the results
HYDRASHIFT reduce the risk of incorrect IF interpretation to improve therapy monitoring.
Easy to implement
Fully integrated into IF protocol without sample pre-treatment for a standardized process compliant to IMWG guidelines.
Follow IMWG guidelines
Process compliant to IMWG guidelines to assess response to treatment in patient with Multiple Myeloma.
Main characteristics
HYDRASHIFT is an immunofixation procedure performed on HYDRAGEL IF 2/4 gel and based on the creation of a mAb/ anti mAb immune complex shift mAb drug (daratumumab or isatuximab) in alpha zone.
This complex is visible in the IgG and kappa immunofixation tracks. A negative HYDRASHIFT result demonstrates the absence of endogenous M-protein.
Serum
Sensitivity
The limit of immune complex visualized is 0.3 g/L.
- HYDRASHIFT 2/4 daratumumab (20 tests) – P/N: 4639
- daratumumab control – P/N: 4765
- HYDRASHIFT 2/4 isatuximab (40 tests) – P/N: 4642
- isatuximab control P/N: 4764
Featured instruments for HYDRASHIFT
See all instrumentsHYDRASYS 2 SCAN FOCUSING
Large menu with high quality results on gel electrophoresis.
Related resources
See all resourcesApr. 11, 2022 Dec. 21, 2024
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
Impact of monoclonal antibody therapies on electrophoresis interpretation in myeloma patients
Educational Webinar with Dr. Rachel WHEELER
Apr. 18, 2024 Apr. 20, 2024
European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
Scientific publications
See all publicationsHYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Interested in HYDRASHIFT?
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.